Preoperative anatomical landmarks and longitudinal HeartMate 3 pump position in X-rays: Relevance for adverse events.
X‐ray
anatomical landmarks
hemocompatibility‐related adverse events
left ventricular assist device
preoperative markers
pump position
Journal
Artificial organs
ISSN: 1525-1594
Titre abrégé: Artif Organs
Pays: United States
ID NLM: 7802778
Informations de publication
Date de publication:
06 Aug 2024
06 Aug 2024
Historique:
revised:
08
07
2024
received:
23
04
2024
accepted:
22
07
2024
medline:
6
8
2024
pubmed:
6
8
2024
entrez:
6
8
2024
Statut:
aheadofprint
Résumé
Left ventricular assist device (LVAD) malposition has been linked to hemocompatibility-related adverse events (HRAEs). This study aimed to identify preoperative anatomical landmarks and postoperative pump position, associated with HRAEs during LVAD support. Pre- and postoperative chest X-ray measures (≤14 days pre-implantation, first postoperative standing, 6, 12, 18, and 24 months post-implantation) were analyzed for their association with HRAEs over 24 months in 33 HeartMate 3 (HM3) patients (15.2% female, age 66 (9.5) years). HM3 patients with any HRAE showed significantly lower preoperative distances between left ventricle and thoracic outline (dLVT) (25.3 ± 10.2 mm vs. 40.3 ± 15.5 mm, p = 0.004). A ROC-derived cutoff dLVT ≤ 29.2 mm provided 85.7% sensitivity and 72.2% specificity predicting any HRAE during HM3 support (76.2% (>29.2 mm) vs. 16.7% (≤29.2 mm) freedom from HRAE, p < 0.001) and significant differences in cardiothoracic ratio (0.58 ± 0.04 vs. 0.62 ± 0.04, p = 0.045). Postoperative X-rays indicated lower pump depths in patients with ischemic strokes (9.1 ± 16.2 mm vs. 38.0 ± 18.5 mm, p = 0.007), reduced freedom from any neurological event (pump depth ≤ 28.7 mm: 45.5% vs. 94.1%, p = 0.004), and a significant correlation between pump depth and inflow cannula angle (r = 0.66, p < 0.001). Longitudinal changes were observed in heart-pump width (F(4,60) = 5.61, p < 0.001). Preoperative X-ray markers are associated with postoperative HRAE occurrence. Applying this knowledge in clinical practice may enhance risk stratification, guide therapy optimization, and improve HM3 recipient management.
Sections du résumé
BACKGROUND
BACKGROUND
Left ventricular assist device (LVAD) malposition has been linked to hemocompatibility-related adverse events (HRAEs). This study aimed to identify preoperative anatomical landmarks and postoperative pump position, associated with HRAEs during LVAD support.
METHODS
METHODS
Pre- and postoperative chest X-ray measures (≤14 days pre-implantation, first postoperative standing, 6, 12, 18, and 24 months post-implantation) were analyzed for their association with HRAEs over 24 months in 33 HeartMate 3 (HM3) patients (15.2% female, age 66 (9.5) years).
RESULTS
RESULTS
HM3 patients with any HRAE showed significantly lower preoperative distances between left ventricle and thoracic outline (dLVT) (25.3 ± 10.2 mm vs. 40.3 ± 15.5 mm, p = 0.004). A ROC-derived cutoff dLVT ≤ 29.2 mm provided 85.7% sensitivity and 72.2% specificity predicting any HRAE during HM3 support (76.2% (>29.2 mm) vs. 16.7% (≤29.2 mm) freedom from HRAE, p < 0.001) and significant differences in cardiothoracic ratio (0.58 ± 0.04 vs. 0.62 ± 0.04, p = 0.045). Postoperative X-rays indicated lower pump depths in patients with ischemic strokes (9.1 ± 16.2 mm vs. 38.0 ± 18.5 mm, p = 0.007), reduced freedom from any neurological event (pump depth ≤ 28.7 mm: 45.5% vs. 94.1%, p = 0.004), and a significant correlation between pump depth and inflow cannula angle (r = 0.66, p < 0.001). Longitudinal changes were observed in heart-pump width (F(4,60) = 5.61, p < 0.001).
CONCLUSION
CONCLUSIONS
Preoperative X-ray markers are associated with postoperative HRAE occurrence. Applying this knowledge in clinical practice may enhance risk stratification, guide therapy optimization, and improve HM3 recipient management.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Artificial Organs published by International Center for Artificial Organ and Transplantation (ICAOT) and Wiley Periodicals LLC.
Références
Yuzefpolskaya M, Schroeder SE, Houston BA, Robinson MR, Gosev I, Reyentovich A, et al. The Society of Thoracic Surgeons Intermacs 2022 annual report: focus on the 2018 heart transplant allocation system. Ann Thorac Surg. 2023;115:311–327.
Jorde UP, Saeed O, Koehl D, Morris AA, Wood KL, Meyer DM, et al. The Society of Thoracic Surgeons Intermacs 2023 annual report: focus on magnetically levitated devices. Ann Thorac Surg. 2024;117:33–44.
Mehra MR, Goldstein DJ, Uriel N, Cleveland JC, Yuzefpolskaya M, Salerno C, et al. Two‐year outcomes with a magnetically levitated cardiac pump in heart failure. N Engl J Med. 2018;378:1386–1395.
Mehra MR, Goldstein DJ, Cleveland JC, Cowger JA, Hall S, Salerno CT, et al. Five‐year outcomes in patients with fully magnetically levitated vs axial‐flow left ventricular assist devices in the MOMENTUM 3 randomized trial. JAMA. 2022;328:1233–1242.
Uriel N, Colombo PC, Cleveland JC, Long JW, Salerno C, Goldstein DJ, et al. Hemocompatibility‐related outcomes in the MOMENTUM 3 trial at 6 months: a randomized controlled study of a fully magnetically levitated pump in advanced heart failure. Circulation. 2017;135:2003–2012.
Nayak A, Hall SA, Uriel N, Goldstein DJ, Cleveland JC, Cowger JA, et al. Predictors of 5‐year mortality in patients managed with a magnetically levitated left ventricular assist device. J Am Coll Cardiol. 2023;82:771–781.
Varshney AS, DeFilippis EM, Cowger JA, Netuka I, Pinney SP, Givertz MM. Trends and outcomes of left ventricular assist device therapy: JACC focus seminar. J Am Coll Cardiol. 2022;79:1092–1107.
Ghodrati M, Maurer A, Schlöglhofer T, Khienwad T, Zimpfer D, Beitzke D, et al. The influence of left ventricular assist device inflow cannula position on thrombosis risk. Artif Organs. 2020;44:939–946.
Taghavi S, Ward C, Jayarajan SN, Gaughan J, Wilson LM, Mangi AA. Surgical technique influences HeartMate II left ventricular assist device thrombosis. Ann Thorac Surg. 2013;96:1259–1265.
Adamson RM, Mangi AA, Kormos RL, Farrar DJ, Dembitsky WP. Principles of HeartMate II implantation to avoid pump malposition and migration. J Card Surg. 2015;30:296–299.
Shah P, Tantry US, Bliden KP, Gurbel PA. Bleeding and thrombosis associated with ventricular assist device therapy. J Heart Lung Transplant. 2017;36:1164–1173.
Bhama JK, Bansal A. Left ventricular assist device inflow cannula position may contribute to the development of HeartMate II left ventricular assist device pump thrombosis. Ochsner J. 2018;18:131–135.
Kilic A, Ransom J, Maltais S, Sun B, Entwistle JW, Bailey S, et al. Pump position impacts HeartMate II left ventricular assist device thrombosis. ASAIO J. 2019;65:227–232.
Imamura T, Adatya S, Chung B, Nguyen A, Rodgers D, Sayer G, et al. Cannula and pump positions are associated with left ventricular unloading and clinical outcome in patients with HeartWare left ventricular assist device. J Card Fail. 2018;24:159–166.
Imamura T, Narang N, Nitta D, Fujino T, Nguyen A, Kim G, et al. Optimal cannula positioning of HeartMate 3 left ventricular assist device. Artif Organs. 2020;44:e509–e519.
Aigner P, Schlöglhofer T, Plunger LC, Beitzke D, Wielandner A, Schima H, et al. Pump position and thrombosis in ventricular assist devices: correlation of radiographs and CT data. Int J Artif Organs. 2021;44:956–964.
Schlöglhofer T, Aigner P, Migas M, Beitzke D, Dimitrov K, Wittmann F, et al. Inflow cannula position as risk factor for stroke in patients with HeartMate 3 left ventricular assist devices. Artif Organs. 2022;46:1149–1157.
Shih H, Butler C, Melehy A, Ning Y, Kurlansky P, Kaku Y, et al. Serial assessment of HeartMate 3 pump position and inflow angle and effects on adverse events. Eur J Cardiothorac Surg. 2021;59:1166–1173.
Chivukula VK, Beckman JA, Prisco AR, Dardas T, Lin S, Smith JW, et al. Left ventricular assist device inflow cannula angle and thrombosis risk. Circ Heart Fail. 2018;11:e004325.
Imamura T, Narang N, Nitta D, Fujino T, Nguyen A, Chung B, et al. HeartWare ventricular assist device cannula position and hemocompatibility‐related adverse events. Ann Thorac Surg. 2020;110:911–917.
Schlöglhofer T, Zapusek L, Wiedemann D, Riebandt J, Wittmann F, Dimitrov K, et al. International normalized ratio test frequency in left ventricular assist device patients affects anticoagulation quality and adverse events. ASAIO J. 2021;67:157–162.
Saeed D, Feldman D, Banayosy AE, Birks E, Blume E, Cowger J, et al. The 2023 International Society for Heart and Lung Transplantation guidelines for mechanical circulatory support: a 10‐year update. J Heart Lung Transplant. 2023;42:e1–222.
Schneider CA, Rasband WS, Eliceiri KW. NIH image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671–675.
Truszkiewicz K, Poręba R, Gać P. Radiological cardiothoracic ratio in evidence‐based medicine. J Clin Med. 2021;10:2016.
Glover L, Baxley WA, Dodge HT. A quantitative evaluation of heart size measurements from chest roentgenograms. Circulation. 1973;47:1289–1296.
Gross C, Schima H, Schlöglhofer T, Dimitrov K, Maw M, Riebandt J, et al. Continuous LVAD monitoring reveals high suction rates in clinically stable outpatients. Artif Organs. 2020;44:E251–E262. https://doi.org/10.1111/aor.13638
Gregoric ID, Cohn WE, Frazier OH. Diaphragmatic implantation of the HeartWare ventricular assist device. J Heart Lung Transplant. 2011;30:467–470.
Adachi I, Guzmán‐Pruneda FA, Jeewa A, Fraser CD, Dean MKE. A modified implantation technique of the HeartWare ventricular assist device for pediatric patients. J Heart Lung Transplant. 2015;34:134–136.
Barabás IJ, Hartyánszky I, Kocher A, Merkely B. A 3D printed exoskeleton facilitates HeartMate III inflow cannula position. Interact Cardiovasc Thorac Surg. 2019;29:644–646.
Miller JR, Singh GK, Woodard PK, Eghtesady P, Anwar S. 3D printing for preoperative planning and surgical simulation of ventricular assist device implantation in a failing systemic right ventricle. J Cardiovasc Comput Tomogr. 2020;14:e172–e174.
Rauch A, Susen S, Zieger B. Acquired von Willebrand syndrome in patients with ventricular assist device. Front Med. 2019;6:7.
Sparrow CT, Nassif ME, Raymer DS, Novak E, LaRue SJ, Schilling JD. Pre‐operative right ventricular dysfunction is associated with gastrointestinal bleeding in patients supported with continuous‐flow left ventricular assist devices. JACC Heart Fail. 2015;3:956–964.
Demirozu ZT, Radovancevic R, Hochman LF, Gregoric ID, Letsou GV, Kar B, et al. Arteriovenous malformation and gastrointestinal bleeding in patients with the HeartMate II left ventricular assist device. J Heart Lung Transplant. 2011;30(8):849–853.
Mehra MR, Netuka I, Uriel N, Katz JN, Pagani FD, Jorde UP, et al. Aspirin and hemocompatibility events with a left ventricular assist device in advanced heart failure: the ARIES‐HM3 randomized clinical trial. JAMA. 2023;330:2171–2181.
Imamura T, Nguyen A, Kim G, Raikhelkar J, Sarswat N, Kalantari S, et al. Optimal haemodynamics during left ventricular assist device support are associated with reduced haemocompatibility‐related adverse events. Eur J Heart Fail. 2019;21:655–662.
Schlöglhofer T, Marschütz A, Combs P, Stonebraker C, Lupo S, Jeevanandam V, et al. Quality of anticoagulation with phenprocoumon and warfarin in left ventricular assist device patients: a multicenter study. ASAIO J. 2023;69:595–601.
Uriel N, Sayer G, Addetia K, Fedson S, Kim GH, Rodgers D, et al. Hemodynamic ramp tests in patients with left ventricular assist devices. JACC Heart Fail. 2016;4:208–217.
Uriel N, Burkhoff D, Rich JD, Drakos SG, Teuteberg JJ, Imamura T, et al. Impact of hemodynamic ramp test‐guided HVAD speed and medication adjustments on clinical outcomes: the RAMP‐IT‐UP multicenter study. Circ Heart Fail. 2019;12:e006067.
Najjar E, Thorvaldsen T, Dalén M, Svenarud P, Hallberg Kristensen A, Eriksson MJ, et al. Validation of non‐invasive ramp testing for HeartMate 3. ESC Heart Fail. 2020;7:663–672.
Cowger JA, Grafton G, Shah P. Avoiding the “set it and forget it mentality”: a need to regularly reassess left ventricular assist device patients for optimal support. J Thorac Cardiovasc Surg. 2020;159:1322–1325.
Boehme AK, Pamboukian SV, George JF, Beasley TM, Kirklin JK, Tallaj J, et al. Anticoagulation control in patients with ventricular assist devices. ASAIO J. 2017;63:759–765.
Nassif ME, LaRue SJ, Raymer DS, Novak E, Vader JM, Ewald GA, et al. Relationship between anticoagulation intensity and thrombotic or bleeding outcomes among outpatients with continuous‐flow left ventricular assist devices. Circ Heart Fail. 2016;9:e002680.
Imamura T, Nguyen A, Chung B, Rodgers D, Sarswat N, Kim G, et al. Association of inflow cannula position with left ventricular unloading and clinical outcomes in patients with HeartMate II left ventricular assist device. ASAIO J. 2019;65:331–335.
Drakos SG, Terrovitis JV, Anastasiou‐Nana MI, Nanas JN. Reverse remodeling during long‐term mechanical unloading of the left ventricle. J Mol Cell Cardiol. 2007;43:231–242.
Marinescu KK, Uriel N, Mann DL, Burkhoff D. Left ventricular assist device‐induced reverse remodeling: it's not just about myocardial recovery. Expert Rev Med Devices. 2017;14:15–26.
Burkhoff D, Topkara VK, Sayer G, Uriel N. Reverse remodeling with left ventricular assist devices. Circ Res. 2021;128:1594–1612.
Shah P, Psotka M, Taleb I, Alharethi R, Shams MA, Wever‐Pinzon O, et al. Framework to classify reverse cardiac remodeling with mechanical circulatory support: the Utah‐Inova stages. Circ Heart Fail. 2021;14:e007991.
Gunawan A, Robson D, Krishnaswamy RJ, Ramanayake A, Kearney K, Muthiah K, et al. Longitudinal analysis left ventricular chamber responses under durable LVAD support. J Heart Lung Transplant. 2024;43:420–431.
Wever‐Pinzon J, Selzman CH, Stoddard G, Wever‐Pinzon O, Catino A, Kfoury AG, et al. Impact of ischemic heart failure etiology on cardiac recovery during mechanical unloading. J Am Coll Cardiol. 2016;68:1741–1752.